Abstract
HIV protease inhibitors are important antiretroviral drugs which have substantially reduced the morbidity and mortality associated with HIV‐1 infection. Recent data have shown relationships between plasma concentrations of the protease inhibitors and clinical response, which makes therapeutic drug monitoring valuable. We have developed and validated an assay, using liquid chromatography coupled with electrospray tandem mass spectrometry (LC/MS/MS), for the routine quantification of the six licensed protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir) and the pharmacologically active nelfinavir metabolite M8 in plasma.
The sample pretreatment consisted of protein precipitation with a mixture of methanol and acetronitrile using only 100 µl of plasma. Chromatographic separation was performed on an Inertsil ODS3 column (50 × 2.0 mm i.d., particle size 5 µm), with a quick stepwise gradient using an acetate buffer (pH 5) and methanol, at a flow rate of 0.5 ml min^−1^. The analytical run time was 5.5 min. The use of a 96‐well plate autosampler allowed batch sizes up to 150 patient samples. The triple‐quadrupole mass spectrometer was operated in the positive ion mode and multiple reaction monitoring was used for drug quantification. The method was validated over the concentration ranges 0.01–10 µg ml^−1^ for indinavir and saquinavir, 0.1–10 µg ml^−1^ for amprenavir, 0.05–10 µg ml^−1^ for nelfinavir and ritonavir, 0.1–20 µg ml^−1^ for lopinavir and 0.01–5 µg ml^−1^ for M8. Saquinavir‐d~5~ and indinavir‐d~6~ were used as internal standards. The coefficients of variation were always <10% for both intra‐day and inter‐day precisions for each compound. Mean accuracies were also between the designated limits (±15%). The validated concentration ranges proved to be adequate in daily practice. This robust and fast LC/MS/MS assay is now successfully applied for routine therapeutic drug monitoring and pharmacokinetic studies in our hospital. Copyright © 2003 John Wiley & Sons, Ltd.